Information Provided By: 
Fly News Breaks for June 29, 2016
ESPR
Jun 29, 2016 | 06:51 EDT
Credit Suisse analyst Vamil Divan downgraded Esperion to Underperform and lowered its price target to $10 from $23 saying the update on the development plans for bempedoic acid leaves him increasingly concerned about the products outlook in the US market. The analyst was surprised that the FDA may not be willing to allow LDL-C as a surrogate endpoint for initial approval but believes there will be significant pressure, and limited upside, on shares until that certainty is obtained, and that process may take years to play out.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
